<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Biomarcadores > DA - CIMA - Oncología - Biomarcadores - Artículos de Revista >

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours
Autor(es) : Vicent, S. (Silvestre)
Lopez-Picazo, J.M. (José M.)
Toledo, G. (Gemma)
Lozano, M.D. (María Dolores)
Torre, W. (Wenceslao)
Garcia-Corchon, C. (C.)
Quero, C. (C.)
Soria, J.C. (J.C.)
Martin-Algarra, S. (Salvador)
Manzano, R.G. (Ramón G.)
Montuenga, L.M. (Luis M.)
Palabras clave : NSCLC
Fecha incorporación: 2004
Editorial : Nature Publishing Group
Versión del editor: http://www.nature.com/bjc/journal/v90/n5/full/6601644a.html
ISSN: 1532-1827
Cita: Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 2004 Mar 8;90(5):1047-1052.
Activation of the ERK1/2 pathway is involved in malignant transformation both in vitro and in vivo. Little is known about the role of activated ERK1/2 in non-small cell lung cancer (NSCLC). The purpose of this study was to characterise the extent of the activation of ERK1/2 by immunohistochemistry in patients with NSCLC, and to determine the relationship of ERK1/2 activation with clinicopathological variables. Specimens from 111 patients with NSCLC (stages I-IV) were stained for P-ERK. Staining for epidermal growth factor receptor (EGFR) and Ki-67 was also performed. In all, 34% of the tumour specimens showed activation for ERK1/2, while normal lung epithelial tissue was consistently negative. There was a strong statistical correlation between nuclear and cytoplasmic P-ERK staining and advanced stages (P<0.05 and P<0.001, respectively), metastatic hilar or mediastinal lymph nodes (P<0.01, P<0.001), and higher T stages (P<0.01, P<0.001). We did not find correlation of nuclear or cytoplasmic P-ERK staining with either EGFR expression or Ki-67 expression. Total ERK1/2 expression was evaluated with a specific ERK1/2 antibody and showed that P-ERK staining was not due to ERK overexpression but rather to hyperactivation of ERK1/2. Patients with a positive P-ERK cytoplasmic staining had a significant lower survival (P<0.05). However, multivariate analysis did not show significant survival difference. Our study indicates that nuclear and cytoplasmic ERK1/2 activation positively correlates with stage, T and lymph node metastases, and thus, is associated with advanced and aggressive NSCLC tumours.
Enlace permanente: http://hdl.handle.net/10171/18817
Aparece en las colecciones: DA - Ciencias - HAP - Artículos de revista
DA - CIMA - Oncología - Biomarcadores - Artículos de Revista

Ficheros en este registro:
Fichero:  22Vicent BJC 2004.pdf
Tamaño:  164,76 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.